MLR对卡瑞利珠单抗治疗食管癌及胃癌疗效预测的研究

Monocyte-to-lymphocyte ratio in estimating the outcome of esophageal and gastric cancer treated with camrelizumab

目的:探讨外周血炎症指标对卡瑞利珠单抗治疗后食管癌、胃癌患者的疗效影响。方法:回顾性收集2019年7月~2022年1月在芜湖市第二人民医院行卡瑞利珠单抗免疫治疗的食管癌及胃癌患者的临床资料及治疗前外周血相关炎症指标[中性粒细胞-淋巴细胞比值(NLR)、血小板-淋巴细胞比值(PLR)、单核细胞-淋巴细胞比值(MLR)、全身免疫炎症指数(SII)],分析各指标与患者预后的关系。结果:多因素Cox回归分析显示,MLR≥0.515不利于上消化道肿瘤患者的疾病控制,并且是影响患者无进展生存期(PFS)和总生存期(OS)的危险因素(P<0.05)。结论:MLR可作为卡瑞利珠单抗治疗上消化道肿瘤的疗效预测指标。

Objective:To observe the impact of inflammatory biomarkers on the prognosis of patients with esophageal and gastric cancer treated with camrelizumab.Methods:The clinical data,together with the peripheral blood inflammatory biomarkers including neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR)and systemic immune-inflammation index(SII),were retrieved from the patients with esophageal and gastric cancer treated with camrelizumab in our hospital between July 2019 and January 2022.Then the relationship between these variables and the prognosis was analyzed in all patients.Results:Multivariate Cox regression analysis showed that higher MLR was adverse to the disease control in patients with upper gastrointestinal tumors and MLR≥0.515 was a risk factor for progression-free survival(PFS)and overall survival(OS)(P<0.05).Conclusion:MLR can be used as a predictive biomarker for the efficacy of upper gastrointestinal tumors treated with camrelizumab.